Randomized trial of l-serine in patients with hereditary sensory and autonomic neuropathy type 1

Vera Fridman, Saranya Suriyanarayanan, Peter Novak, William David, Eric A Macklin, Diane McKenna-Yasek, Kailey Walsh, Razina Aziz-Bose, Anne Louise Oaklander, Robert Brown, Thorsten Hornemann, Florian Eichler, Vera Fridman, Saranya Suriyanarayanan, Peter Novak, William David, Eric A Macklin, Diane McKenna-Yasek, Kailey Walsh, Razina Aziz-Bose, Anne Louise Oaklander, Robert Brown, Thorsten Hornemann, Florian Eichler

Abstract

Objective: To evaluate the safety and efficacy of l-serine in humans with hereditary sensory autonomic neuropathy type I (HSAN1).

Methods: In this randomized, placebo-controlled, parallel-group trial with open-label extension, patients aged 18-70 years with symptomatic HSAN1 were randomized to l-serine (400 mg/kg/day) or placebo for 1 year. All participants received l-serine during the second year. The primary outcome measure was the Charcot-Marie-Tooth Neuropathy Score version 2 (CMTNS). Secondary outcomes included plasma sphingolipid levels, epidermal nerve fiber density, electrophysiologic measurements, patient-reported measures, and adverse events.

Results: Between August 2013 and April 2014, we enrolled and randomized 18 participants, 16 of whom completed the study. After 1 year, the l-serine group experienced improvement in CMTNS relative to the placebo group (-1.5 units, 95% CI -2.8 to -0.1, p = 0.03), with evidence of continued improvement in the second year of treatment (-0.77, 95% CI -1.67 to 0.13, p = 0.09). Concomitantly, deoxysphinganine levels dropped in l-serine-treated but not placebo-treated participants (59% decrease vs 11% increase; p < 0.001). There were no serious adverse effects related to l-serine.

Conclusion: High-dose oral l-serine supplementation appears safe in patients with HSAN1 and is potentially effective at slowing disease progression.

Clinicaltrialsgov identifier: NCT01733407.

Classification of evidence: This study provides Class I evidence that high-dose oral l-serine supplementation significantly slows disease progression in patients with HSAN1.

Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.

Figures

Figure 1. Trial profile
Figure 1. Trial profile
Figure 2. Change in primary endpoints
Figure 2. Change in primary endpoints
Charcot-Marie-Tooth Neuropathy Score (CMTNS) and Charcot-Marie-Tooth Examination Score (CMTES) in patients taking l-serine vs placebo during the trial period. Baseline values were normalized to zero, and data represent the mean change from baseline. At week 48, patients on placebo crossed over to l-serine (red arrows). I bars indicate 95% confidence bounds.
Figure 3. Change in plasma sphingolipid levels
Figure 3. Change in plasma sphingolipid levels
Change in plasma levels of canonical sphingolipids (A, B) and neurotoxic 1-deoxysphingolipids (C, D) over the course of the study. Baseline values were normalized to zero. Data represent the mean change from baseline. The correlation between the Charcot-Marie-Tooth Neuropathy Score (CMTNS) and deoxysphingosine levels is plotted for baseline (E) and change at 48-week follow-up (F). I bars indicate 95% confidence bounds.
Figure 4. Change in epidermal nerve fiber…
Figure 4. Change in epidermal nerve fiber density (ENFD)
Skin biopsies from the standard distal leg site (lower calf) were largely devoid of epidermal nerve fibers and demonstrated an increase in ENFD at 1 year (p = 0.014) (A). Skin biopsies from the upper thigh revealed no significant change in ENFD in participants taking placebo vs serine (B). Correlation between changes in ENFD in the lower calf and changes in plasma deoxysphingosine levels is shown in (C).

References

    1. Houlden H, King R, Blake J, et al. . Clinical, pathological and genetic characterization of hereditary sensory and autonomic neuropathy type 1 (HSAN I). Brain 2006;129:411–425.
    1. Bejaoui K, Wu C, Scheffler MD, et al. . SPTLC1 is mutated in hereditary sensory neuropathy, type 1. Nat Genet 2001;27:261–262.
    1. Dawkins JL, Hulme DJ, Brahmbhatt SB, Auer-Grumbach M, Nicholson GA. Mutations in SPTLC1, encoding serine palmitoyltransferase, long chain base subunit-1, cause hereditary sensory neuropathy type I. Nat Genet 2001;27:309–312.
    1. Eichler FS, Hornemann T, McCampbell A, et al. . Overexpression of the wild-type SPT1 subunit lowers desoxysphingolipid levels and rescues the phenotype of HSAN1. J Neurosci 2009;29:14646–14651.
    1. Penno A, Reilly MM, Houlden H, et al. . Hereditary sensory neuropathy type 1 is caused by the accumulation of two neurotoxic sphingolipids. J Biol Chem 2010;285:11178–11187.
    1. Jun BK, Chandra A, Kuljis D, Schmidt BP, Eichler FS. Substrate availability of mutant SPT alters neuronal branching and growth cone dynamics in dorsal root ganglia. J Neurosci 2015;35:13713–13719.
    1. Dohrn MF, Othman A, Hirshman SK, et al. . Elevation of plasma 1-deoxy-sphingolipids in type 2 diabetes mellitus: a susceptibility to neuropathy? Eur J Neurol 2015;22:806–814, e855.
    1. Hammad SM, Baker NL, El Abiad JM, et al. . Increased plasma levels of select deoxy-ceramide and ceramide species are associated with increased odds of diabetic neuropathy in type 1 diabetes: a pilot study. Neuromolecular Med 2016;19:46–56.
    1. Zuellig RA, Hornemann T, Othman A, et al. . Deoxysphingolipids, novel biomarkers for type 2 diabetes, are cytotoxic for insulin-producing cells. Diabetes 2014;63:1326–1339.
    1. Garofalo K, Penno A, Schmidt BP, et al. . Oral L-serine supplementation reduces production of neurotoxic deoxysphingolipids in mice and humans with hereditary sensory autonomic neuropathy type 1. J Clin Invest 2011;121:4735–4745.
    1. de Koning TJ. Treatment with amino acids in serine deficiency disorders. J Inherit Metab Dis 2006;29:347–351.
    1. Low PA. Composite autonomic scoring scale for laboratory quantification of generalized autonomic failure. Mayo Clin Proc 1993;68:748–752.
    1. England JD, Gronseth GS, Franklin G, et al. . Practice parameter: evaluation of distal symmetric polyneuropathy: role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review): report of the American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and American Academy of Physical Medicine and Rehabilitation. Neurology 2009;72:177–184.
    1. Zitomer NC, Mitchell T, Voss KA, et al. . Ceramide synthase inhibition by fumonisin B1 causes accumulation of 1-deoxysphinganine: a novel category of bioactive 1-deoxysphingoid bases and 1-deoxydihydroceramides biosynthesized by mammalian cell lines and animals. J Biol Chem 2009;284:4786–4795.
    1. Fridman V, Oaklander AL, David WS, et al. . Natural history and biomarkers in hereditary sensory neuropathy type 1. Muscle Nerve 2015;51:489–495.
    1. Dedov VN, Dedova IV, Merrill AH Jr, Nicholson GA. Activity of partially inhibited serine palmitoyltransferase is sufficient for normal sphingolipid metabolism and viability of HSN1 patient cells. Biochim Biophys Acta 2004;1688:168–175.
    1. McCampbell A, Truong D, Broom DC, et al. . Mutant SPTLC1 dominantly inhibits serine palmitoyltransferase activity in vivo and confers an age-dependent neuropathy. Hum Mol Genet 2005;14:3507–3521.
    1. Bode H, Bourquin F, Suriyanarayanan S, et al. . HSAN1 mutations in serine palmitoyltransferase reveal a close structure-function-phenotype relationship. Hum Mol Genet 2016;25:853–865.
    1. Verhamme C, van Schaik IN, Koelman JH, de Haan RJ, de Visser M. The natural history of Charcot-Marie-Tooth type 1A in adults: a 5-year follow-up study. Brain 2009;132:3252–3262.
    1. Smith AG, Howard JR, Kroll R, et al. . The reliability of skin biopsy with measurement of intraepidermal nerve fiber density. J Neurol Sci 2005;228:65–69.
    1. Shy ME, Chen L, Swan ER, et al. . Neuropathy progression in Charcot-Marie-Tooth disease type 1A. Neurology 2008;70:378–383.
    1. Lewis RA, McDermott MP, Herrmann DN, et al. . High-dosage ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A: results of a randomized, double-masked, controlled trial. JAMA Neurol 2013;70:981–987.
    1. Kugathasan UEM, Laurá M, Sinclair C, et al. . Natural history study in hereditary sensory neuropathy type 1 (HSN1): improving the responsiveness of outcome measures. Peripheral Nerve Society annual meeting; 2017: 81.
    1. Morrow JM, Sinclair CD, Fischmann A, et al. . MRI biomarker assessment of neuromuscular disease progression: a prospective observational cohort study. Lancet Neurol 2016;15:65–77.
    1. Othman A, Bianchi R, Alecu I, et al. . Lowering plasma 1-deoxysphingolipids improves neuropathy in diabetic rats. Diabetes 2015;64:1035–1045.
    1. Othman A, Saely CH, Muendlein A, et al. . Plasma 1-deoxysphingolipids are predictive biomarkers for type 2 diabetes mellitus. BMJ Open Diabetes Res Care 2015;3:e000073.
    1. Mwinyi J, Bostrom A, Fehrer I, et al. . Correction: plasma 1-deoxysphingolipids are early predictors of incident type 2 diabetes mellitus. PLoS One 2017;12:e0179313.
    1. Othman A, Rutti MF, Ernst D, et al. . Plasma deoxysphingolipids: a novel class of biomarkers for the metabolic syndrome? Diabetologia 2012;55:421–431.
    1. Kramer R, Bielawski J, Kistner-Griffin E, et al. . Neurotoxic 1-deoxysphingolipids and paclitaxel-induced peripheral neuropathy. FASEB J 2015;29:4461–4472.
    1. Kiya T, Kawamata T, Namiki A, Yamakage M. Role of satellite cell-derived L-serine in the dorsal root ganglion in paclitaxel-induced painful peripheral neuropathy. Neuroscience 2011;174:190–199.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera